Screener
Palvella Therapeutics PVLA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 200,000,000 shares authorized; 14,313,659 and 12,380,933 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 14 | 12 |
| Additional paid-in capital | 383,421 | 163,338 |
| Accumulated other comprehensive (loss) income | 95 | 83 |
| Accumulated deficit | (151,217) | (135,450) |
| Total stockholders’ equity | 232,313 | 27,983 |
| Total liabilities and stockholders’ equity | $263,759 | $59,559 |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's total equity?
- Palvella Therapeutics (PVLA) reported total equity of $232.31M in Q1 2026.
- How has Palvella Therapeutics's total equity changed year-over-year?
- Palvella Therapeutics's total equity increased by 318.0% year-over-year, from $55.58M to $232.31M.
- What is the long-term trend for Palvella Therapeutics's total equity?
- Over 5 years (2020 to 2025), Palvella Therapeutics's total equity has grown at a -2.0% compound annual growth rate (CAGR), from $31.03M to $27.98M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Palvella Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude